Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.
Company Details
- Employees
- 13
- Founded
- -
- Address
- 265 Franklin Street,
- in****@****ria.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imbria.com
- HQ
- Boston, Massachusetts
Imbria Pharmaceuticals Questions
Imbria Pharmaceuticals's website is imbria.com
Imbria Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/imbria
Imbria Pharmaceuticals has
13 employees.
View email and phone details for 13
employees at Imbria Pharmaceuticals.
Imbria Pharmaceuticals's industry is
Biotechnology Research
Imbria Pharmaceuticals's top competitors are
Sunbird Bio,
Stylus Medicine,
Marengo Therapeutics,
Scismic,
Nona Biosciences,
Incendia Therapeutics,
Stellaromics Inc.,
Pledge Therapeutics,
Qld Biotherapeutics Inc,
Climb Bio.
Imbria Pharmaceuticals's support email address is investorrelations@imbria.com
Imbria Pharmaceuticals's categories are Biotechnology Research
Imbria Pharmaceuticals's founding year is 2018
